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Edited by Jesus AvilaAbstract Truncated tau protein is the characteristic feature of
human sporadic Alzheimer’s disease. We have identiﬁed trun-
cated tau proteins conformationally diﬀerent from normal
healthy tau. Subpopulations of these structurally diﬀerent tau
species promoted abnormal microtubule assembly in vitro sug-
gesting toxic gain of function. To validate pathological activity
in vivo we expressed active form of human truncated tau protein
as transgene, in the rat brain. Its neuronal expression led to the
development of the neuroﬁbrillary degeneration of Alzheimer’s
type. Furthermore, biochemical analysis of neuroﬁbrillary
changes revealed that massive sarcosyl insoluble tau complexes
consisted of human Alzheimer’s tau and endogenous rat tau in
ratio 1:1 including characteristic Alzheimer’s disease (AD)-spe-
ciﬁc proteins (A68). This work represents ﬁrst insight into the
possible causative role of truncated tau in AD neuroﬁbrillary
degeneration in vivo.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Tau cascade1. Introduction
Neuroﬁbrillary structures in Alzheimer’s disease are princi-
pally composed of hyperphosphorylated tau [1–4] and truncated
forms of tau protein [2,5,6]. It has been shown that truncation is
closely associated with Alzheimer’s disease (AD)-typical
conformational changes of the tau protein [5–10]. We have
hypothesized that truncation could play major role in AD tau
pathology [11]. This hypothesis originated from ﬁnding that
AD-speciﬁc monoclonal antibody 423 (mAb 423) recognizes
truncated tau species in the core of paired helical ﬁlaments
(PHF) of Alzheimer’s disease [5,6,12,13]. Furthermore, mAb
DC11, raised against sporadic AD-brain derived tau extracts,
recognized all and only those tau proteins that were truncated
at the N-terminus or at both, the N- and C- termini [8]. Trun-Abbreviations: AD, Alzheimer’s disease; mAb, monoclonal antibody;
NFT, neuroﬁbrillary tangle; NT, neuropil threads; OD, optical dens-
ity; PHF, paired helical ﬁlaments; SDS–PAGE, sodium dodecyl sulf-
ate–polyacrylamide gel electrophoresis
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doi:10.1016/j.febslet.2006.05.029cated tauproteins fromsporadic cases of humanAD, recognized
by mAb DC11 (‘‘Tau DC11 state’’), were further tested in vitro
for their potency to promote microtubule assembly. The sub-
populations of these truncated tau species induced abnormal
microtubule assemblies, suggesting toxic gain of function. In or-
der to elucidate the role of truncated tau in AD tau cascade we
used truncated tau that was the most active in promotion of
abnormal microtubule assembly, as a transgene in the rat brain.
Rats displayedmassive neuroﬁbrillary structures induced by ex-
pressed human truncated tau.This is for the ﬁrst time shown that
truncated human tau could serve as a driving force in neurode-
generation of AD type in vivo.2. Materials and methods
2.1. Preparation, expression and puriﬁcation of tau proteins
The preparation of cDNA coding for human tau isoforms and trun-
cated tau proteins was described elsewhere [6]. All DNA constructs
were cloned in pET17 vector (Novagen) through NdeI–EcoRI restric-
tion sites. Integrity of each construct was veriﬁed by DNA sequence
analysis (ABI Prism 377DNA Sequencer, Perkin–Elmer). Tau proteins
were expressed in Escherichia coli and puriﬁed from bacterial lysates by
ion-exchange chromatography [14]. The protein concentration was
determined by BCA kit (Pierce, USA).
2.2. Microtubule assembly
Tubulin for microtubule assembly assay was isolated from pig
brains, using reversible assembly puriﬁcation method [15]. Assay mix-
tures contained 1 mg/ml tubulin, 1 mM GTP, recombinant tau pro-
teins (0.2 mg/ml) in assembly buﬀer (100 mM Pipes, pH 6,9; 1 mM
MgSO4 and 2 mM EGTA). After gentle and rapid mixing, the samples
were pipetted into quartz microcuvettes and equilibrated at 37 C in a
thermostatically controlled spectrophotometer (Beckman Coulter).
The turbidity was continuously monitored at 340 nm for a period of
5 min. For electron microscopy samples were ﬁxed with 1% glutaralde-
hyde, put on the formvar/carbon coated 400 mesh copper grid (Agar
Scientiﬁc, UK) and stained with 1% aqueous uranyl acetate.
2.3. Preparation of transgene construct and generation of transgenic rats
The transgene construct was prepared by ligation of a cDNA coding
for human tau protein truncated at amino acid positions 151–391, into
the mouse Thy-1 gene downstream of the brain promoter/enhancer se-
quence. The original Thy-1 gene sequence coding for exons II–IV, to-
gether with thymus enhancer sequence was replaced by the cDNA.
Transgenic DNA was linearized by cleavage with EcoRI. Vector se-
quences were removed prior to microinjection. Transgenic rats were
generated by pronuclear injection of one-day old SHR rat embryos.
Founders were double screened by PCR using Thy-1-speciﬁc and hu-
man tau-speciﬁc primers amplifying START and STOP codon ﬂank-
ing sequences. The rat endogenous tau sequence was used as an
internal ampliﬁcation control. Two independent transgenic founderblished by Elsevier B.V. All rights reserved.
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engineered and displayed similar phenotype. The studies described be-
low were performed using the line #318. The expression level of total
human truncated tau in the transgenic rats was determined by Western
blot analysis using protein extracts from diﬀerent areas of brain and
spinal cord.
2.4. Monoclonal antibodies
HT7 (Innogenetics, Belgium) recognizes residues 159–163 of human
tau, AT8 (Innogenetics) recognizes phosphoserine 202 and 205, AT180
(Innogenetics) recognizes phosphothreonine 231, PHF 1 (a kind gift
from Dr. Peter Davies) recognizes phosphoserine 396 and 404. As a
control we have used pan tau antibody DC25 recognizing residues
347–354 (Axon Neuroscience, Austria).
2.5. Histology and immunohistochemistry
Animals were perfused transcardially with 4% paraformaldehyde in
0.1 M phosphate buﬀered saline, pH 7.2, and the tissues were post-ﬁxed
after perfusion and then cut on cryotome or embedded in paraﬃn and
cut on microtome. Immunohistochemistry and histopathology were
performed on 50 lm free-ﬂoating and 8 lm paraﬃn embedded sec-
tions. Tissue sections were immunostained using the standard avidin–
biotin–peroxidase method. The modiﬁed Gallyas silver iodide, Congo
red and Thioﬂavin S staining methods were utilized to demonstrate
mature neuroﬁbrillary pathology in neurons [16,17]. Sections were
examined with an Olympus BX51 and Zeiss Axiovert 200 microscopes.
2.6. Stereological analysis
The quantiﬁed parameters were neuronal and neuroﬁbrillary tangle
(NFT) density. The left brain stems of 10 months old transgenic males
were sectioned on cryostat in the frontal plane. The rostral part of the
gigantocellular reticular nucleus was selected as a representative region
of the reticular formation of the brain stem. NFTs were immunohisto-
chemically visualized using mAb AT8 and thereafter the sections were
counterstained with cresyl violet. The optical disector principle was ap-
plied [18], particles (neurons, NFTs) were counted and numerical den-
sities per mm3 were calculated. The obtained results were corrected to
the number weighted ﬁnal section thickness [19] to eliminate any pos-
sible bias in the data due to shrinkage of the sections during histolog-
ical processing. The study was realized with the aid of a computer-
based stereological system (StereoInvestigator, MicroBrightField,
USA).
2.7. Extraction of sarcosyl insoluble tau
Sarcosyl insoluble tau was isolated from brain tissues of 3–12
months old rats based on the modiﬁed method of Greenberg and Da-
vies [20]. Approximately 2 g of brain tissue was homogenized in 10 vol-
umes of buﬀer (10 mM Tris, 0.8 M NaCl, 1 mM EGTA and 10%
sucrose, pH 7.4) and centrifuged at 27200 · g for 20 min. The superna-
tant was adjusted to 1% (w/v) N-lauroylsarcosine and incubated 1 h at
RT. After the incubation supernatant was spun at 123000 · g for 1 h at
RT. Resulted pellet was resuspended in small volume of phosphate-
buﬀered saline and analysed in Western blot and throughout the paper
is designated as P2.
2.8. Western blotting
Sarcosyl insoluble tau proteins puriﬁed from brains were analyzed
on 5–20% SDS–PAGE gradient gel and Western blot as described pre-
viously [14]. Enhanced chemiluminescence developed Western blot was
digitalized with LAS3000 CCD imaging system (Fujiﬁlm, Japan). Den-
sitometric data analysis and relative quantiﬁcation of Western blot re-
cord were performed by AIDA Biopackage (Raytest, Germany) as
described [14].3. Results
3.1. Truncated tau protein (t151-391) induces abnormal
assembly of microtubules in vitro
Monoclonal antibody DC11, raised using AD brain derived
truncated forms of tau proteins, recognizes ‘‘Tau DC11 state’’that represents all and only those truncated tau proteins that
are conformationally diﬀerent from normal healthy tau pro-
teins (Fig. 1A–C). The eﬀect of these truncated tau proteins
on the assembly of microtubules was analyzed. The physiolog-
ical function of healthy tau is characterized mainly by promo-
tion of microtubule assembly. The tau eﬃciency in promotion
of microtubule assembly can be measured by increase in opti-
cal density at 340 nm. DC11 positive truncated tau species, ex-
cept t99-441, displayed signiﬁcantly higher microtubule
assembly promotion activity than normal healthy tau. Short
amino-terminal truncation (t99-441) produces no measurable
diﬀerence from normal tau. Strikingly N- and C-terminally
truncated tau species are promoting robust microtubule assem-
bly, 3–4 times higher (OD340:1.2–1.6) than normal healthy tau
(OD340:0.4) (Fig. 1D). For electron microscopy analysis of
microtubule assembly was selected mAb DC11 positive double
truncated tau species (t151-391) and normal healthy tau
(t1-441). Electron micrographs show that normal tau induces
formation of thin microtubular networks (Fig. 1E). However,
interaction of truncated tau species (t151-391) with tubulin
produces abnormally thick microtubular networks (bundles),
(Fig. 1F), diﬀerent in their appearance from normal microtu-
bules under the same magniﬁcation (3600·).3.2. AD-like neuroﬁbrillary pathology induced by truncated tau
(t151-391) in vivo
To validate suggested pathological function of truncated tau
in vivo, we generated transgenic rat that overexpressed trun-
cated tau (t151-391) in the brain and spinal cord (Fig. 2).
The most prominent histopathological feature of transgenic
rats was extensive argyrophilic NFT formation (Fig. 3A). No
neuroﬁbrillary pathology was found in wild type rats through-
out their lifespan. The appearance of NFTs satisﬁed several
histological criteria used to identify neuroﬁbrillary degenera-
tion in the human AD including argyrophilia (Fig. 3A), Congo
red birefringence (Fig. 3B) and Thioﬂavin S reactivity
(Fig. 3C).
The load of neuroﬁbrillary pathology was stereologically
quantiﬁed in the brain stem (gigantocellular reticular nucleus)
where the mean NFT density was 690/mm3 with an observed
coeﬃcient of variation of 32.9% (Fig. 3D). The mean NFT:
neuron ratio was 1:8 in transgenic animals. Furthermore,
immunohistochemical analysis revealed that neuroﬁbrillary
tangle formation passed through the histologically well-deﬁned
maturation stages. The ﬁrst stage was characterized by intra-
neuronal pre-tangles, immunoreactive for phosphorylated tau
protein. The antibody AT8 detected the diﬀuse rod-like phos-
pho-tau accumulations within the cytoplasm. The pre-tangle
bearing neurons had detectable nuclei and normal appearance
(Fig. 3E). The assembly of pre-tangles resulted in formation of
intracellular NFTs in cell bodies (Fig. 3F) and in processes as
neuropil threads (NTs). The late developmental stage repre-
sented extra-neuronal ‘‘ghost’’ tangles (eNFT) that were pres-
ent as immunoreactive, densely packed tau ﬁbrils or bundles
outside the neurons (Fig. 3G). The cell soma revealed no stain-
able cytoplasm and nucleus.3.3. The sarcosyl insoluble tau complexes consisted of human
truncated tau and endogenous rat tau protein
To determine whether truncated tau (t151-391) was able to
induce maturation of neuroﬁbrillary pathology, manifested
Fig. 1. Eﬃcacy of truncated tau proteins in promotion of microtubule assembly. (A) Schematic diagram of tau species tested in vitro for their
potency to promote microtubule assembly. The numbering of amino acids corresponds to that of the human tau 40 [30]. (B, C) Western blot analysis
of tau proteins using pan tau mAb DC25 and tau conformation speciﬁc mAb DC11. Recombinant human tau six isoforms (6i) were used as a
control. Monoclonal antibody DC25 (B) recognizes all tau proteins, however conformation-dependent mAb DC11 (C) stains only truncated forms of
tau proteins and does not recognize any of six human tau isoforms. (D) Microtubule assembly induced by truncated tau proteins monitored by
turbidometry at OD 340 nm at 5 min. Individual bars reﬂect eﬃcacy of tau species tested in promotion of microtubule assembly. (E, F) Electron
microscopy images of microtubules induced by normal tau (E) and truncated tau (F). Samples were taken at steady state of polymerization (at 5 min).
Both ﬁgures are at the same magniﬁcation (3600·).
Fig. 2. Expression proﬁle of human truncated tau in the brain and spinal cord of transgenic animals. (A) Pan tau monoclonal antibody DC25 was
used for staining of rat endogenous and human truncated tau protein in diﬀerent brain regions and spinal cord. (B) Transgenic protein expression
levels were 2–5-fold over endogenous tau in the isocortex, hippocampus, diencephalon, brain stem and the spinal cord.
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lysed sarcosyl insoluble protein extracts (P2) from 10 to 12
months old transgenic rats, age-matched control rats (wt)
and from Alzheimer’s diseased brain tissues. Western blot
analysis of P2 fraction, from transgenic rat using pan tau
mAb DC25, revealed similar staining pattern to that of hu-
man AD brain (Fig. 4, lanes 3 and 7). Age-matched control
wild type rats had no tau in P2 fraction (Fig. 4, lane 2).
To investigate whether human truncated tau (t151-391) co-assembled with endogenous rat tau in transgenic rats, we
analyzed the P2 fraction with antibodies reactive with both
human and rat tau (DC25), with human tau only (HT7)
and with endogenous rat tau only (PHF1, human Alzheimer’s
truncated tau – transgene – does not contain the PHF1 epi-
tope). Our results showed that sarcosyl insoluble P2 fractions
from transgenic rats consisted of human tau (Fig. 4, lane 4)
and rat endogenous tau (Fig. 4, lane 5). Phosphorylated
tau immunoreactivities were detected in the same fraction
Fig. 3. Truncated tau induced AD-like neuroﬁbrillary degeneration in vivo. (A) Development of extensive argyrophylic positive neuroﬁbrillary
tangles in 9 months old rats. High magniﬁcation of Congo red (B) and Thioﬂavin S positive (C) intraneuronal tangles showed similar appearance as
in human AD. (D) Stereological analysis of rat brains expressing human truncated tau showed a mean neuronal density of 5703 neurons/mm3
(S.E.M. = 250.2) in brain stem. The estimated NFT density in this brain region was 690/mm3 (S.E.M. = 101.4). Ontogeny of the neuroﬁbrillary
degeneration in these rats is similar to that of human Alzheimer’s disease: pre-tangles (E), intracellular tangles (F) and extracellular tangles (G). Tool
bars 10 lm.
Fig. 4. Human truncated tau and endogenous rat tau are constituent
parts of massive sarcosyl insoluble tau complexes. The series of
ultracentrifugation and extraction steps was used to obtain sarcosyl
insoluble fraction of tau (P2 fraction) from brain tissues of age-
matched wild type (wt) rats, transgenic rats and human AD brain
tissues. Recombinant human six tau isoforms (lane 1) were used as a
control. Wild type rats did not show any sarcosyl insoluble tau (lane
2). Immunoblotting of P2 fraction from transgenic rats revealed
sarcosyl insoluble complexes of tau (lane 3, mAb DC25) that were
formed from human truncated tau (lane 4, HT7-human tau-speciﬁc
mAb), endogenous phosphorylated rat tau (lane 5, mAb PHF1-
endogenous rat tau speciﬁc, see Section 3), and human and rat
phosphorylated tau (lane 6, mAb AT8). P2 fraction of human AD is
shown as a positive control with characteristic A68 triplet (lane 7, mAb
DC25, lane 8, mAb PHF1) seen in rats as well (lane 5).
N. Zilka et al. / FEBS Letters 580 (2006) 3582–3588 3585(P2) with phosphorylation-dependent antibodies, AT8 and
PHF1. AT8 phosphoserines 202 and 205 were present in both
human and rat tau (Fig. 4, lane 6). Abnormal phosphoryla-
tion of rat endogenous tau was detected by PHF1 that does
not recognize human truncated tau (Fig. 4, line 5). Further-
more, it is noteworthy that the A68 triplet characteristic of
human AD neuroﬁbrillary degeneration (Fig. 4, lane 8) as
revealed by PHF1 staining was found in transgenic animals
as well (Fig. 4, lane 5).3.4. Quantitative analyses of human transgenic and endogenous
rat tau in sarcosyl insoluble fraction
We examined further the composition of mature sarcosyl
insoluble tau complexes with respect to the ratio between
the transgenic human truncated tau (t151-391) and endoge-
nous rat tau. Insoluble P2 fractions from 12 months old rats
were assayed on Western blot together with three respective
sarcosyl soluble (S2) fractions. Both soluble and insoluble
fractions were stained with pan-tau monoclonal antibody
DC25 (Fig. 5A) and with human tau-speciﬁc monoclonal
antibody HT7 (Fig. 5B). Data from immunoblotted trans-
genic human tau in S2 fractions were digitized and used
as a standard for normalization of monoclonal antibodies
staining. Both antibodies stained tau protein with similar
intensities (Fig. 5E). Tau staining in P2 fraction was
digitized as well (Fig. 5C and D) and the relative tau protein
amount was calculated on the basis of correlation between
amounts of proteins seen by both antibodies. The
comparison of normalized peak areas revealed that mature
sarcosyl insoluble tau complexes are composed of transgenic
human truncated tau and endogenous rat tau at 1:1 ratio
(Fig. 5F).3.5. The level of sarcosyl insoluble formation correlates with
lifespan of transgenic rats expressing truncated tau
Sarcosyl insolubility of tau is generally considered to be a
deﬁnitive transformation point of physiological tau into
pathological form. Therefore, we analysed development of
sarcosyl insoluble tau complexes in the brain of transgenic
rats expressing truncated tau (t151-391). The brain tissues
were examined at 3, 6, 9 and 12 months old animals. The
level of tau in the sarcosyl insoluble P2 fraction increased
in an age-dependent manner and correlated positively with
the development of neuroﬁbrillary pathology. First sarcosyl
insoluble tau consisting exclusively of transgene – human
truncated tau – appeared in the brain of 3 months old
transgenic rats and persisted until the late stages of
neurodegeneration (Fig. 6A, lanes 1, 2). The ﬁrst, phosphor-
ylation induced electrophoretic mobility decrease (gel shift)
Fig. 5. Quantitative analyses of human transgenic and endogenous rat tau in sarcosyl insoluble fraction. The fractions containing sarcosyl insoluble
tau (P2) were analyzed with pan tau monoclonal antibody DC25 and human tau-speciﬁc antibody HT7. Lanes 1–3 show sarcosyl soluble fraction
(S2) from three independent transgenic animals; lane 4 shows sarcosyl insoluble fraction (P2) from transgenic animal (A, B). Boxed oﬀ are P2
fractions (A, B; lane 4) that were used for quantiﬁcation (C, D). Integrated signals from S2 fractions (A, B; lanes 1–3) were used for construction of
the correlation line (E). Ratio between human transgenic and endogenous rat tau in P2 fraction is 1:1 (F). The mAb DC25 staining reﬂects the total
amount of tau present in sarcosyl insoluble P2 pellets, whereas HT7 detects human transgenic tau only.
Fig. 6. Ontogenesis of sarcosyl insoluble tau complexes. (A) Ontogenesis of sarcosyl insoluble tau complexes (P2) in the brain of 3, 6, 9 and 12
months old transgenic rats was monitored by Western blot analysis using pan tau mAb DC25. (B) Alzheimer’s tau expression impact on lifespan of
transgenic rats.
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months old animals (Fig. 6A, lane 3). Mature sarcosyl insol-
uble tau formations, characterized by the presence of tau
species with high and low molecular weight, appeared in
12 months old animals (Fig. 6A, lane 4). It is noteworthy
that the stage of ‘‘mature sarcosyl insoluble tau formation’’
correlated with death of animals expressing transgenic hu-
man truncated tau. The lifespan of hemizygous animals
was 10–12 months and that of homozygotes was 5–6
months. Life expectation of wild type rats is 22–24 months.
These results show that expression of human truncated tau
shortens lifespan in hemizygotes by 50% and in homozygotes
by 75% (Fig. 6B).4. Discussion
During the work providing molecular proof that microtu-
bule associated protein tau is a major (if not sole) constituent
of paired helical ﬁlaments [2,21], it was noted that tau could be
truncated. Molecular mapping of the epitope of monoclonal
antibody 423, that recognizes tau protein derived from AD
brains, revealed for the ﬁrst time that tau is truncated at
E391 in Alzheimer’s disease [6,12]. Since then, truncation of
tau was suggested by many authors as a possible seminal event
in the pathogenesis of Alzheimer’s disease [22–24]. It is gener-
ally agreed that tau has to undergo signiﬁcant conformational
change(s) leading to the pathological polymerization process.
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tion of tau in vitro [25–27]. Despite of these results, the role of
truncation and truncated tau in AD cascade remains an open
issue. Monoclonal antibody DC11, produced against AD
brain derived truncated forms of tau protein, revealed the pres-
ence of conformationally distinct forms of tau protein in AD.
Molecular analysis of these forms showed that DC11 recog-
nizes all and only those N- and C-terminally truncated tau pro-
teins that are conformationally diﬀerent from normal healthy
tau proteins [8]. The shift of tau into ‘‘DC11 state’’ in AD
could represent a new pathogenic entity and important step
in neuroﬁbrillary degeneration itself. Therefore, we studied
eﬀect of N- and C-terminally truncated tau species, on their
capacity to inﬂuence microtubule assembly. Strikingly, these
double truncated tau species promoted robust microtubule
assembly, that was 3–4 times higher (OD340:1.2–1.6) than
microtubule assembly induced by normal healthy tau
(OD340:0.4). Electron microscopy analysis of microtubules
assembled by DC11 tau species revealed abnormally thick
microtubular networks (bundles) that diﬀered from normal
microtubular networks. These results suggest that the trun-
cated tau has large impact on microtubule assembly in vitro
suggesting its possible gain of altered function that could lead
to tau transformation into a pathological entity.
In order to explore the possible role of truncated tau in vivo,
we expressed the most in vitro active DC11 tau species (t151-
391) as a transgene in rat brains. Transgenic animals developed
extensive neuroﬁbrillary pathology satisfying several histopa-
thological criteria used for identiﬁcation of neuroﬁbrillary
degeneration in AD, including argyrophilia, Congo red bire-
fringence and Thioﬂavin S reactivity. As in human AD, forma-
tion of NFT in transgenic animals passed through several
histologically deﬁned maturation stages. First stage was repre-
sented by pre-tangle formation (identiﬁed with mAb AT8) that
is considered to be an early event in NFT development [28,29].
The second stage was characterized by formation of intracellu-
lar argyrophilic NFTs in neuronal cell bodies and NTs in their
processes. The late developmental stage in these transgenic ani-
mals was represented by the presence of extra-neuronal
‘‘ghost’’ tangles (eNFT). The well-deﬁned staging in transgenic
rats expressing truncated tau oﬀers an opportunity to study the
neurodegenerative cascade of tau protein in vivo.
In human sporadic AD, mature neuroﬁbrillary degeneration
is characterized by extensive formation of sarcosyl insoluble
tau protein complexes consisting of abnormally hyperphos-
phorylated full length and truncated tau forms [1–4]. The anal-
ysis of sarcosyl insoluble tau fractions derived from the brain
of transgenic animals allowed drawing several important
conclusions: First, sarcosyl insoluble tau complexes were
composed of transgenic human truncated tau and endogenous
rat tau at a 1:1 ratio. Second, both human and endogenous rat
tau were phosphorylated (AT8) and third, tau A68 triplet
pattern characteristic of human AD [3] was formed in trans-
genic animals. Furthermore, detailed time course experiments
of neuroﬁbrillary maturation revealed that ﬁrst sarcosyl insol-
uble truncated tau monomer appeared already in very young
transgenic animals (3 months old), well before the detection
of intraneuronal tangles (9 months old). We suggest that sarco-
syl insoluble monomer (‘‘one band stage’’) represents imma-
ture developmental stage of sarcosyl insoluble complex
formations. Further ‘‘aging’’ of sarcosyl insoluble tau is repre-
sented by intensive phosphorylation (‘‘stage of shifted mono-mer’’). Most probably the phosphorylated monomers led to
the development of mature sarcosyl insoluble tau complexes
(‘‘stage of tau ladder’’) encompassing both truncated and
endogenous full-length tau (9–12 months old). It is intriguing
that the stage of ‘‘mature sarcosyl insoluble tau formation’’
correlated with the death of animals expressing transgenic hu-
man truncated tau. The life span of hemizygous animals was
10–12 months and that of homozygotes was 5–6 months. Life
expectation of wild type rats is 22–24 months. Thus truncated
tau expression shortens life span of hemizygotes by 50% and of
homozygotes by 75%.
The present study provides experimental data introducing
truncated tau protein as an important upstream factor in the
pathogenesis of neuroﬁbrillary degeneration of AD type. In
addition, our data established that truncated tau is suﬃcient
to drive neuroﬁbrillary degeneration in the absence of tau
mutation.
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